Fourth-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).
Igor Stukalin(University of Calgary), Daniel Yick Chin Heng(University of Calgary), Brian I. Rini(Vanderbilt University Medical Center), Hao‐Wen Sim(The University of Sydney), Benoit Beuselinck(Universitair Ziekenhuis Leuven), Connor Wells(Queen Mary University of London), Ravindran Kanesvaran(University of Ioannina), Felice Pasini(Ospedale Civile Di Ivrea), Aristotelis Bamias(National and Kapodistrian University of Athens), Camillo Porta(University of Pavia), Toni K. Choueiri(Harvard University), Frede Donskov(Aarhus University Hospital), I. Alex Bowman(The University of Texas Southwestern Medical Center), Jae‐Lyun Lee(Ulsan College), Anna Paola Fraccon, Raphael Brandão Moreira(Dana-Farber Cancer Institute), Sandy Srinivas(Stanford University), Neeraj Agarwal(University of Utah), James Brugarolas(The University of Texas Southwestern Medical Center), Sun Young Rha(Yonsei University)
Cited by 5
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k